Lung Cancer and The Financial FallI have been living with stage 4 lung cancer for almost 10 years now. Planning out my life 3-4 months at a time is a regular thing for me. Many... By Samantha MixonBookmark for later Reactions 0 reactions Comments4 comments
Research Opportunity: Health LiteracyThere is a new opportunity to participate in a research study about health literacy. Health Literacy Media shares more. We are Health Literacy Media, a non-profit organization based in St... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
U.S. Preventative Services Task Force Issues New Recommendation for Lung Cancer ScreeningThe United States Preventive Services Task Force (USPSTF) has issued 2021 guidelines for lung cancer screening. The last change made to these guidelines was in 2013. A screening test is... By Editorial TeamBookmark for later Reactions 0 reactions Comments9 comments
FDA Approves Cosela™ (trilaciclib) to Reduce Bone Marrow Suppression Caused by ChemotherapyThe U.S. Food and Drug Administration (FDA) has approved Coselsa (trilaciclib) to protect bone marrow from damage caused by chemotherapy. Coselsa is approved for use in adults receiving certain types... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
American Cancer Society Releases 2021 Report on CancerThe American Cancer Society (ACS) has released its 2021 report on cancer, called Cancer Facts and Figures 2021. The data in this report is 2 to 4 years behind the... By Editorial TeamBookmark for later Reactions 0 reactions Comments1 comments
Tagrisso® (osimertinib) Approved As Adjuvant Therapy for NSCLCThe U.S. Food and Drug Administration (FDA) has granted a new indication (use) for Tagrisso® (osimertinib). The latest indication is for adjuvant therapy after tumor resection (removal) in people with... By Editorial TeamBookmark for later Reactions 0 reactions Comments2 comments
Zepzelca Approved For Second-Line Treatment Of SCLCThe United States Food and Drug Administration (US FDA) has approved Zepzelca for the treatment of small cell lung cancer (SCLC). Zepzelca (lurbinectedin) is specifically used for adults whose cancer... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
FDA Approves Tecentriq for First-Line Treatment of Metastatic NSCLCThe United States Food and Drug Administration (US FDA) has expanded the use of Tecentriq for non-small cell lung cancer (NSCLC). Tecentriq (atezolizumab) has been approved in the past for... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
FDA Approves Opdivo and Yervoy As First Combined Immunotherapy for NSCLCThe United States Food and Drug Administration (US FDA) has approved the use of Opdivo (nivolumab) and Yervoy (ipilimumab) together for non-small cell lung cancer (NSCLC). Opdivo (nivolumab) and Yervoy... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
The Experience In America: Small Cell Lung CancerLung cancer is the second most common cancer in both men and women accounting for 13 percent of all new cancers. Approximately 15 percent of all lung cancers are small... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
Imfinzi Approved For Extensive-Stage Small-Cell Lung CancerThe United States Food and Drug Administration (US FDA) has approved the drug Imfinzi (durvalumab) for small-cell lung cancer. Imfinzi is specifically for people with small-cell lung cancer that has... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
(Closed) Take the Fatigue and Health Survey!The 2020 Fatigue and Health survey has now closed. Thank you for your interest! We are excited to share the results with you soon.Exhaustion, tiredness, weariness... fatigue. We know chronic... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
FDA Grants Breakthrough Therapy Designation to JNJ-6372 in Metastatic Non-Small Cell Lung CancerThe US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-6372 to Janssen Pharmaceutical, a Johnson & Johnson Company. NJ-6372 is an investigational treatment for metastatic non-small... By Editorial TeamBookmark for later Reactions 0 reactions Comments2 comments
FDA Makes Way for Experimental Drugs to Fight COVID-19On March 19, the U.S. Food and Drug Administration (FDA) approved the testing of two drugs, chloroquine (hydroxychloroquine) and remdesivir, to treat people with COVID-19. The drugs have been given... By Editorial TeamBookmark for later Reactions 0 reactions Comments3 comments
Breaking Down The Results From LUNGevity’s ScorecardIn its Lung Cancer Scorecard, LUNGevity Foundation grades each state on its access to care and lung cancer statistics. Based on their analysis, over half of the states receive a... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
COVID-19: Tips To Reduce Your RiskWith all of the news circulating about the novel (new) coronavirus, it can be easy to feel overwhelmed or anxious. This is especially true if you are immune-compromised due to... By Editorial TeamBookmark for later Reactions 0 reactions Comments1 comments
COVID-19 Basics for the Immune-CompromisedFor those living with chronic health conditions, current news about the coronavirus (COVID-19) can be anxiety-inducing. We have questions and concerns about how the virus is transmitted, how it can... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
Survival Rate Increasing in Lung CancerPeople with lung cancer are living longer. This is a key finding of The State of Lung Cancer 2019 report issued by the American Lung Association. The survival rate for... By Editorial TeamBookmark for later Reactions 0 reactions Comments2 comments
The American Cancer Society Issues 2020 Report on CancerThe American Cancer Society (ACS) recently released its report, Cancer Statistics, 2020. The report found that the death rate from cancer in the US is dropping. Between 1991 and 2017... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
FDA Grants HSB-1216 Orphan Drug Designation for Small Cell Lung CancerHillstream BioPharma announced that it has been granted FDA orphan drug designation (ODD) for HSB-1216 for the treatment of small cell lung cancer (SCLC).1-2 QUATRAMER salinomycin is a new formulation... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
